+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Erythropoietin Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • PDF Icon

    Report

  • 144 Pages
  • November 2023
  • Region: Global
  • IMARC Group
  • ID: 5911812
The global erythropoietin drugs market size reached US$ 10.4 Billion in 2022. Looking forward, the market is expected to reach US$ 14.5 Billion by 2028, exhibiting a growth rate (CAGR) of 5.70% during 2022-2028. The growing prevalence of anemia and cancer, increasing application in treating chronic kidney disease, and rising awareness among the masses about the potential effects of the drug represent some of the key factors driving the market.

Erythropoietin (EPO) drugs comprise various drugs, such as epoetin-alfa, epoetin-beta, and darbepoetin-alfa, that are consumed to cure EPO deficiency in the body. They are manufactured synthetically using recombinant deoxyribonucleic acid (DNA) technology. They stimulate the production of red blood cells (RBCs) in bone marrow and regulate the concentration of hemoglobin in the body. They assist in enhancing endurance, reducing tiredness, increasing metabolism, and improving the healing process of muscles while maintaining a healthy amount of erythrocytes in the body. They are utilized to treat various diseases, such as anemia, end-stage renal disease, human immunodeficiency virus (HIV), and hematology, among individuals. Besides this, EPO drugs are consumed by athletes to enhance their performance and aerobic capacity, as they benefit in increasing the availability of oxygen to their muscles.

Erythropoietin Drugs Market Trends

At present, the rising demand for EPO drugs among the masses due to the increasing prevalence of cancer and neurological diseases, such as autism, brain tumors, cerebral palsy, epilepsy, and attention deficit disorder (ADD), among individuals represents one of the key factors supporting the growth of the market. Besides this, the growing awareness among the masses about the EPO drugs and their effectiveness is offering a positive market outlook. Additionally, there is a rise in the need for surgical interventions among the masses around the world. This, coupled with the increasing utilization of EPO drugs to reduce allogeneic blood transfusions after surgical procedures in patients, is propelling the growth of the market. Apart from this, the rising number of chronic kidney disease (CKD) cases among individuals across the globe are offering lucrative growth opportunities to industry investors. Moreover, various benefits offered by EPO drugs, such as increasing red blood cells (RBCs) and reducing fatigue, are positively influencing the market. In addition to this, the rapid commercialization of erythropoietin biosimilars around the world is impelling the growth of the market. This, coupled with the increasing preference for biosimilar drugs rather than reference drugs across the globe, is contributing to the growth of the market. Furthermore, the rising utilization of EPO drugs as novel therapeutic agents in research institutes for numerous research purposes is strengthening the growth of the market.

Key Market Segmentation

This research provides an analysis of the key trends in each sub-segment of the global erythropoietin drugs market report, along with forecasts at the global, regional and country level from 2023-2028. The report has categorized the market based on drug class, product type, application and end user.

Drug Class Insights:

  • Biologics
  • Biosimilars
The report has provided a detailed breakup and analysis of the erythropoietin drugs market based on the drug class. This includes biologics and biosimilars. According to the report, biologics represented the largest segment.

Product Type Insights:

  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
A detailed breakup and analysis of the erythropoietin drugs market based on the product type has also been provided in the report. This includes epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. According to the report, epoetin-alfa accounted for the largest market share.

Application Insights:

  • Hematology
  • Kidney Disorder
  • Cancer
A detailed breakup and analysis of the erythropoietin drugs market based on the application has also been provided in the report. This includes hematology, kidney disorder, cancer, and others. According to the report, kidney disorder accounted for the largest market share.

End-User Insights:

  • Hospitals
  • Homecare
  • Specialty Clinics
A detailed breakup and analysis of the erythropoietin drugs market based on the end-user has also been provided in the report. This includes hospitals, homecare, specialty clinics, and others. According to the report, hospitals accounted for the largest market share.

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Latin America
  • Brazil
  • Mexico
  • Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for erythropoietin drugs. Some of the factors driving the North America erythropoietin drugs market included the increasing approvals of erythropoietin drugs, various incentives offered by governing agencies for research on chronic diseases, rising prevalence of cancer among individuals, etc.

Competitive Landscape

The report has also provided a comprehensive analysis of the competitive landscape in the global erythropoietin drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Amgen Inc., Biocon Limited, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., Johnson & Johnson, LG Chem Ltd., Pfizer Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

1. How big is the global erythropoietin drugs market?
2. What is the expected growth rate of the global erythropoietin drugs market during 2023-2028?
3. What are the key factors driving the global erythropoietin drugs market?
4. What has been the impact of COVID-19 on the global erythropoietin drugs market?
5. What is the breakup of the global erythropoietin drugs market based on the drug class?
6. What is the breakup of the global erythropoietin drugs market based on the product type?
7. What is the breakup of the global erythropoietin drugs market based on the application?
8. What is the breakup of the global erythropoietin drugs market based on the end-user?
9. What are the key regions in the global erythropoietin drugs market?
10. Who are the key players/companies in the global erythropoietin drugs market?

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Erythropoietin Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 Biologics
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Biosimilars
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Product Type
7.1 Epoetin-alfa
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Epoetin-beta
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Darbepoetin-alfa
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Application
8.1 Hematology
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Kidney Disorder
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Cancer
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by End User
9.1 Hospitals
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Homecare
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Specialty Clinics
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Amgen Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Biocon Limited
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 Dr. Reddy’s Laboratories Ltd.
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 F. Hoffmann-La Roche AG
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.5 Intas Pharmaceuticals Ltd.
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.6 Johnson & Johnson
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 LG Chem Ltd.
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Pfizer Inc.
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Sun Pharmaceutical Industries Limited
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Teva Pharmaceutical Industries Ltd.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis

Companies Mentioned

  • Amgen Inc.
  • Biocon Limited
  • Dr. Reddy’s Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • LG Chem Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information